Rutgers New Jersey Medical School (NJMS) has been selected by Parexel International, a global biopharmaceutical services provider, as a Key Alliance Site. This will give NJMS ongoing, long-term access to trial opportunities through Parexel’s client base.
NJMS will provide Parexel with the opportunity to place early to late phase studies, exposure to experienced investigators for clinical trial design and access to information resources through the NJMS electronic medical record system. This integrated arrangement will further enable Paraexel and NJMS to plan, develop and execute clinical trial studies with shorter timelines.
“Our collaboration with Parexel will further strengthen the capabilities of New Jersey Medical School’s clinical research center unit, which conducts clinical trials in a wide variety of medical specialties,” says William C. Gause, senior associate dean for research at NJMS, which became part of the newly created Rutgers Biomedical and Health Sciences unit within Rutgers in July.
“This partnership further enhances the global research, educational and service missions of the entire new Rutgers, as it strengthens both our clinical research capabilities and our potential to enhance health care delivery for the people throughout the state,” said Kenneth Breslauer, vice president for health science partnerships at Rutgers.
Clinical trials hosted at the NJMS clinical research center unit will evaluate medications and other products designed to treat a wide range of conditions, including cancer, obesity and diabetes as well as cardiovascular, respiratory and infectious diseases. Many trials will be conducted through collaboration with University Hospital, the flagship teaching hospital for New Jersey Medical School.
“Ultimately, Parexel and NJMS are aligning and mobilizing knowledge and resources to bring new products to market through more efficient clinical trials,” said Lollo Eriksson, Parexel’s vice president, clinical research services and global site alliances.
Established in 1766, Rutgers, The State University of New Jersey, is America’s eighth oldest institution of higher learning and a public research university. Rutgers Biomedical and Health Sciences (RBHS) is the healthcare education, research and clinical division of Rutgers University, comprising nine schools and their attendant faculty practices, centers, institutes and clinics; New Jersey’s comprehensive cancer care center; and New Jersey's largest behavioral healthcare network.
